

Tregalizumab

Cat. No.:	HY-P99327
CAS No.:	1207446-68-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies ^{[1][2][3]} .									
IC ₅₀ & Target	CD4 ^{[1][2][3]} .									
In Vitro	<p>Tregalizumab is able to activate the suppressive capacity of regulatory T cells^[1].</p> <p>Tregalizumab reduces proliferation and cytokine secretion when isolated PBMCs are stimulated with tetanus toxoid in a dose-dependent manner^[1].</p> <p>Tregalizumab (0-30 µg/mL; 18 h) treatment of PBMC induces CD4 down-modulation of T cells^[2].</p> <p>Tregalizumab primarily induces CD4 down-modulation at inflammatory sites^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table><tr><td>Cell Line:</td><td>PBMC cells</td></tr><tr><td>Concentration:</td><td>0-30 µg/mL</td></tr><tr><td>Incubation Time:</td><td>18 h</td></tr><tr><td>Result:</td><td>Induced CD4 down-modulation of T cells.</td></tr></table>		Cell Line:	PBMC cells	Concentration:	0-30 µg/mL	Incubation Time:	18 h	Result:	Induced CD4 down-modulation of T cells.
Cell Line:	PBMC cells									
Concentration:	0-30 µg/mL									
Incubation Time:	18 h									
Result:	Induced CD4 down-modulation of T cells.									

REFERENCES

- [1]. König M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11.
- [2]. Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308.
- [3]. Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA